Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: Patient Selection and Reported Outcomes

References

• Sanabria A, Kowalski LP, Shah JP, et al. Growing incidence of thyroid carcinoma in recent years: factors underlying overdiagnosis. Head Neck. 2018;40(4):855–866. doi:10.1002/hed.25029
   PubMed Web of Science ®Google Scholar
• SEER. SEER program coding and staging manual 2023; 2023.
   Google Scholar
• Watkinson J. Thyroid cancer: a comprehensive guide to clinical management. Ann R Coll Surg Engl. 2008;90(4):360. doi:10.1308/003588408X286026i
   Google Scholar
• Porter A, Wong DJ. Perspectives on the treatment of advanced thyroid cancer: approved therapies, resistance mechanisms, and future directions. Front Oncol. 2020;10:592202. doi:10.3389/fonc.2020.592202
   PubMed Web of Science ®Google Scholar
• Shonka DC, Ho A, Chintakuntlawar AV, et al. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment. Head Neck. 2022;44(6):1277–1300. doi:10.1002/hed.27025
   PubMed Web of Science ®Google Scholar
• Girolami I, Pantanowitz L, Mete O, et al. Programmed death-ligand 1 (PD-L1) Is a potential biomarker of disease-free survival in papillary thyroid carcinoma: a systematic review and meta-analysis of PD-L1 immunoexpression in follicular epithelial derived thyroid carcinoma. Endocr Pathol. 2020;31(3):291–300. doi:10.1007/s12022-020-09630-5
   PubMed Web of Science ®Google Scholar
• Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/tumor-node-metastasis Staging System for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? Thyroid. 2017;27(6):751–756. doi:10.1089/thy.2017.0102
   PubMed Web of Science ®Google Scholar
• PubMed. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Available from: https://pubmed.ncbi.nlm.nih.gov/26462967/. Accessed March 10, 2023.
   Google Scholar
• Haddad RI, Nasr C, Bischoff L, et al. NCCN guidelines insights: thyroid carcinoma, version 2.2018. J Natl Compr Canc Netw. 2018;16(12):1429–1440. doi:10.6004/jnccn.2018.0089
   PubMed Web of Science ®Google Scholar
• Paz-Fumagalli R, Li X, Smallridge RC. Ethanol ablation of neck metastases from differentiated thyroid carcinoma. Semin Intervent Radiol. 2019;36(5):381–385. doi:10.1055/s-0039-1696651
   PubMed Web of Science ®Google Scholar
• Kiess AP, Agrawal N, Brierley JD, et al. External-beam radiotherapy for differentiated thyroid cancer locoregional control: a statement of the American Head and Neck Society. Head Neck. 2016;38(4):493–498. doi:10.1002/hed.24357
   PubMed Web of Science ®Google Scholar
• Aashiq M, Silverman DA, Na’ara S, Takahashi H, Amit M. Radioiodine-refractory thyroid cancer: molecular basis of redifferentiation therapies, management, and novel therapies. Cancers. 2019;11(9):1382. doi:10.3390/cancers11091382
   PubMed Web of Science ®Google Scholar
• Molenaar RJ, Sidana S, Radivoyevitch T, et al. Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer. J Clin Oncol. 2018;36(18):1831–1839. doi:10.1200/JCO.2017.75.0232
   PubMedGoogle Scholar
• Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630. doi:10.1056/NEJMoa1406470
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–328. doi:10.1016/S0140-6736(14)60421-9
   PubMed Web of Science ®Google Scholar
• Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383(9):825–835. doi:10.1056/NEJMoa2005651
   PubMed Web of Science ®Google Scholar
• Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, Phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9(8):491–501. doi:10.1016/S2213-8587(21)00120-0
   PubMed Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739. doi:10.1056/NEJMoa1714448
   PubMed Web of Science ®Google Scholar
• Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):271–282. doi:10.1016/S1470-2045(19)30691-6
   PubMed Web of Science ®Google Scholar
• Brose MS, Robinson B, Sherman SI, et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(8):1126–1138. doi:10.1016/S1470-2045(21)00332-6
   PubMed Web of Science ®Google Scholar
• Brose MS, Cabanillas ME, Cohen EEW, et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, Phase 2 trial. Lancet Oncol. 2016;17(9):1272–1282. doi:10.1016/S1470-2045(16)30166-8
   PubMed Web of Science ®Google Scholar
• Busaidy NL, Konda B, Wei L, et al. Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial. Thyroid. 2022;32(10):1184–1192. doi:10.1089/thy.2022.0115
   PubMed Web of Science ®Google Scholar
• Chu E, Jr VTD. Physicians’ Cancer Chemotherapy Drug Manual 2021. Jones & Bartlett Learning; 2020.
   Google Scholar
• Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–3646. doi:10.1200/JCO.2012.48.4659
   PubMed Web of Science ®Google Scholar
• Fallahi P, Di bari F, Ferrari SM, et al. Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther. 2015;9:3459–3470. doi:10.2147/DDDT.S72495
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Elisei R, Müller S, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol. 2017;28(11):2813–2819. doi:10.1093/annonc/mdx479
   PubMed Web of Science ®Google Scholar
• Capdevila J, Robinson B, Sherman SI, et al. Cabozantinib versus placebo in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: outcomes in prespecified subgroups based on histology subtypes. JCO. 2022;40(16_suppl):6081. doi:10.1200/JCO.2022.40.16_suppl.6081
   Web of Science ®Google Scholar
• Hernando J, Capdevila J, Robinson B, et al. Cabozantinib (C) versus placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy: outcomes in prespecified subgroups based on prior VEGFR-targeted therapy. JCO. 2022;40(16_suppl). doi:10.1200/JCO.2022.40.16_suppl.6083
   Google Scholar
• ClinicalTrials.gov. Effect of cabozantinib S-malate or lenvatinib mesylate on weight and body composition in patients with metastatic endocrine cancer - full text view. Available from: https://clinicaltrials.gov/ct2/show/NCT02592356. Accessed March 10, 2023.
   Google Scholar
• Thomas Jefferson University. A phase II trial of cabozantinib for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting. clinicaltrials.gov; 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT02041260. Accessed March 10, 2023.
   Google Scholar
• National Cancer Institute (NCI). Phase II study of XL184 (Cabozantinib) in combination with nivolumab and ipilimumab (CaboNivoIpi) in patients with radioiodine-refractory differentiated thyroid cancer whose cancer progressed after one prior VEGFR-targeted therapy. clinicaltrials.gov; 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT03914300. Accessed March 10, 2023.
   Google Scholar
• Exelixis. A Phase 1b dose-escalation study of cabozantinib (XL184) administered alone or in combination with atezolizumab to subjects with locally advanced or metastatic solid tumors. clinicaltrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03170960. Accessed March 10, 2023.
   Google Scholar
• Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18:60. doi:10.1186/s12943-019-0974-6
   PubMed Web of Science ®Google Scholar
• Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325–340. doi:10.1038/nrclinonc.2018.29
   PubMed Web of Science ®Google Scholar
• Grupo Espanol de Tumores Neuroendocrinos. Exploratory basket trial of cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system. CABATEN Study. clinicaltrials.gov; 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT04400474. Accessed March 10, 2023.
   Google Scholar
• National Cancer Institute (NCI). Pilot trial of nivolumab plus cabozantinib for advanced solid tumors in patients with HIV infection. clinicaltrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT04514484. Accessed March 10, 2023.
   Google Scholar
• National Cancer Institute (NCI). Phase 2 Trial of XL184 (Cabozantinib) an oral small-molecule inhibitor of multiple kinases, in children and young adults with refractory sarcomas, Wilms tumor, and other rare tumors. clinicaltrials.gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT02867592. Accessed March 10, 2023.
   Google Scholar
• Exelixis. A randomized, double-blind study to evaluate the efficacy and safety of cabozantinib (XL184) at 60 mg/day compared to a 140 mg/day in progressive, metastatic medullary thyroid cancer patients. clinicaltrials.gov; 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT01896479. Accessed March 10, 2023.
   Google Scholar
• Exelixis. An open-label, expanded access study of cabozantinib (XL184) in subjects with unresectable, locally advanced, or metastatic medullary thyroid cancer. clinicaltrials.gov; 2013. Available from: https://clinicaltrials.gov/ct2/show/NCT01683110. Accessed March 10, 2023.
   Google Scholar